Hematologic Malignancy
Indolent Non-Hodgkin Lymphoma
CI-CAN-00005564Explore in graph →
Hematologic212 active trials12 approved drugs2 evidence items
- NCIt
- C8504
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00005564Explore in graph →
Clinical trials
791 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (150)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05543070 | Low-dose Radiotherapy in iNHL | unknown | Phase 2 | 73 | Chinese Academy of Medical SciencesOTHER | 1 | Sep 16, 2022 | clinicaltrials |
| NCT03905135 | Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies | completed | Phase 1 | 8 | National Cancer Institute (NCI)NIH | 1 | Sep 13, 2022 | clinicaltrials |
| Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma(IRIS) |
| completed |
| Phase 2 |
| 20 |
| Andres J. M. FerreriOTHER |
| 1 |
| Aug 4, 2022 |
| clinicaltrials |
| NCT04665115 | Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19) | withdrawn | Phase 2 | 0 | Academic and Community Cancer Research UnitedOTHER | 1 | Aug 3, 2022 | clinicaltrials |
| NCT02793583 | Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma(UNITY-NHL) | terminated | Phase 2 / Phase 3 | 710 | TG Therapeutics, Inc.INDUSTRY | 9 | Jul 21, 2022 | clinicaltrials |
| NCT04796922 | To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302) | withdrawn | Phase 3 | 0 | Incyte CorporationINDUSTRY | 0 | Jul 18, 2022 | clinicaltrials |
| NCT02049541 | Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma | completed | Phase 1 | 18 | Kami Maddocks, MDOTHER | 1 | Jun 30, 2022 | clinicaltrials |
| NCT02710643 | "MIRO" Molecularly Oriented Immuno-radio-therapy(FIL_MIRO) | completed | Phase 2 | 110 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Jun 21, 2022 | clinicaltrials |
| NCT04836832 | Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma | withdrawn | Phase 1 | 0 | Narendranath EpperlaOTHER | 0 | Jun 7, 2022 | clinicaltrials |
| NCT01261247 | Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | completed | Phase 2 | 41 | Mayo ClinicOTHER | 1 | May 24, 2022 | clinicaltrials |
| NCT03682796 | Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma | completed | Phase 1 | 32 | Triphase Research and Development III Corp.INDUSTRY | 2 | May 19, 2022 | clinicaltrials |
| NCT02883517 | Cell-free Circulating DNA in Primary Cutaneous Lymphomas(MATULILA) | completed | — | 35 | University Hospital, BordeauxOTHER | 1 | May 13, 2022 | clinicaltrials |
| NCT01744912 | Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies | terminated | Phase 1 | 10 | TG Therapeutics, Inc.INDUSTRY | 1 | May 11, 2022 | clinicaltrials |
| NCT02677324 | Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia | completed | Phase 2 | 33 | Dana-Farber Cancer InstituteOTHER | 1 | May 11, 2022 | clinicaltrials |
| NCT03713320 | SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides(SOLAR) | terminated | Phase 2 | 37 | miRagen Therapeutics, Inc.INDUSTRY | 8 | Apr 8, 2022 | clinicaltrials |
| NCT04491825 | Diagnostic Classifier for Cutaneous T-cell Lymphomas | unknown | — | 160 | Medical University of ViennaOTHER | 1 | Apr 5, 2022 | clinicaltrials |
| NCT05003141 | PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies | unknown | Phase 1 | 110 | Qilu Puget Sound Biotherapeutics (dba Sound Biologics)INDUSTRY | 3 | Mar 28, 2022 | clinicaltrials |
| NCT04465162 | Radiation Therapy Alone for the Treatment of Stage 1 and 2 Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma | completed | Phase 2 | 75 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT04955340 | A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat | completed | Phase 1 | 5 | 4SC AGINDUSTRY | 1 | Feb 18, 2022 | clinicaltrials |
| NCT05205902 | TOtal Skin Electron Beam Therapy (Low-dose) for Tumor Clone Eradication in Early-stage Mycosis Fungoides(TOTEM-01) | not yet recruiting | Phase 3 | 78 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Jan 25, 2022 | clinicaltrials |
| NCT02323659 | Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas | terminated | Phase 4 | 100 | Polish Lymphoma Research GroupNETWORK | 1 | Jan 13, 2022 | clinicaltrials |
| NCT01445535 | Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Nov 3, 2021 | clinicaltrials |
| NCT01381692 | Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma | completed | Phase 1 / Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Oct 4, 2021 | clinicaltrials |
| NCT01805037 | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas | terminated | Phase 1 / Phase 2 | 20 | Northwestern UniversityOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT00113802 | Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia | terminated | Phase 2 | 31 | Gilead SciencesINDUSTRY | 1 | Aug 19, 2021 | clinicaltrials |
| NCT01728207 | Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL | terminated | Phase 1 | 30 | Gilead SciencesINDUSTRY | 1 | Aug 19, 2021 | clinicaltrials |
| NCT00546793 | Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL | completed | Phase 1 / Phase 2 | 32 | Gilead SciencesINDUSTRY | 1 | Aug 16, 2021 | clinicaltrials |
| NCT02640287 | Expression of Ku70/XRCC6 in Waldenström's Macroglobulinemia(WAL-KU) | completed | N/A | 55 | Central Hospital, Nancy, FranceOTHER | 1 | Aug 6, 2021 | clinicaltrials |
| NCT02928510 | Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic Lymphoma | terminated | — | 1 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 14, 2021 | clinicaltrials |
| NCT02933320 | BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia | completed | Phase 1 / Phase 2 | 14 | Cancer Research UKOTHER | 1 | Jul 8, 2021 | clinicaltrials |
| NCT04952974 | B-cell Chronic Lymphoid Malignancies Markers(MALYZOMA-II) | unknown | — | 420 | University Hospital, Strasbourg, FranceOTHER | 1 | Jul 7, 2021 | clinicaltrials |
| NCT03869619 | REal World Data in LYmphoma and Survival in Adults(REALYSA) | recruiting | — | 6,000 | Hospices Civils de LyonOTHER | 1 | Jun 28, 2021 | clinicaltrials |
| NCT01592981 | Randomised Trial in Waldenstrom's Macroglobulinaemia(R2W) | completed | Phase 2 | 60 | University College, LondonOTHER | 1 | Jun 18, 2021 | clinicaltrials |
| NCT02945319 | Integrated Molecular and Clinical Profiling to Optimize Outcome Prediction in Splenic Marginal Zone Lymphoma | completed | — | 373 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 1 | Jun 7, 2021 | clinicaltrials |
| NCT02669017 | Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) | completed | Phase 1 | 183 | ADC Therapeutics S.A.INDUSTRY | 3 | May 19, 2021 | clinicaltrials |
| NCT02037256 | Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma | completed | N/A | 23 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | May 10, 2021 | clinicaltrials |
| NCT02689869 | Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma(Alternative) | unknown | Phase 2 | 98 | Ludwig-Maximilians - University of MunichOTHER | 1 | May 7, 2021 | clinicaltrials |
| NCT01046006 | Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia | completed | Phase 2 | 59 | Meletios A. DimopoulosOTHER | 3 | Apr 30, 2021 | clinicaltrials |
| NCT02301494 | Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma(CTCL) | withdrawn | N/A | 0 | Rochester General HospitalOTHER | 0 | Apr 27, 2021 | clinicaltrials |
| NCT02341209 | Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma(CTCL) | terminated | Phase 2 | 1 | Rochester General HospitalOTHER | 1 | Apr 27, 2021 | clinicaltrials |
| NCT01125293 | Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia | terminated | Phase 1 / Phase 2 | 46 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 23, 2021 | clinicaltrials |
| NCT00536601 | High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors | completed | N/A | 174 | Roswell Park Cancer InstituteOTHER | 1 | Apr 22, 2021 | clinicaltrials |
| NCT01678443 | Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies | terminated | Phase 1 | 2 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 2, 2021 | clinicaltrials |
| NCT02165397 | Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia | completed | Phase 3 | 181 | Pharmacyclics LLC.INDUSTRY | 9 | Mar 3, 2021 | clinicaltrials |
| NCT00489203 | Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 140 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT00936611 | LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia | completed | Phase 2 | 39 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 28, 2021 | clinicaltrials |
| NCT04431089 | Efficacy and Safety of SHC014748M in Patients With Relapsed or Refractory Follicular (FL) or Marginal Zone (MZL) Lymphoma | unknown | Phase 2 | 122 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 1 | Jan 28, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Sep 16, 2022source: clinicaltrials